BioLife Solutions (BLFS) to Post Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect BioLife Solutions to announce earnings of ($0.01) per share and revenue of $27.7960 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. The company had revenue of $27.50 million during the quarter, compared to analyst estimates of $25.66 million. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Stock Down 1.5%

BLFS stock opened at $31.50 on Thursday. BioLife Solutions has a twelve month low of $17.86 and a twelve month high of $33.14. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -393.70 and a beta of 1.94. The firm’s fifty day simple moving average is $27.42 and its two-hundred day simple moving average is $23.65.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BLFS. Stephens reaffirmed an “equal weight” rating and set a $31.00 price target (down from $32.00) on shares of BioLife Solutions in a research note on Monday. Wall Street Zen lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Saturday, July 25th. Lake Street Capital downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and reduced their price target for the stock from $33.00 to $31.00 in a research note on Wednesday, July 22nd. HC Wainwright lowered shares of BioLife Solutions from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $32.00 to $31.00 in a report on Thursday, July 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BioLife Solutions has an average rating of “Hold” and a consensus target price of $31.38.

Insider Activity at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $23.70, for a total value of $15,405,000.00. Following the completion of the sale, the insider owned 4,757,165 shares of the company’s stock, valued at approximately $112,744,810.50. This represents a 12.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 1,200,000 shares of company stock valued at $28,125,000. Insiders own 2.20% of the company’s stock.

Institutional Trading of BioLife Solutions

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company raised its position in shares of BioLife Solutions by 2.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock worth $447,000 after acquiring an additional 555 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in BioLife Solutions by 2.6% in the second quarter. Thrivent Financial for Lutherans now owns 27,278 shares of the medical equipment provider’s stock valued at $588,000 after purchasing an additional 702 shares during the last quarter. Quarry LP raised its holdings in BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 713 shares in the last quarter. Millennium Management LLC lifted its position in shares of BioLife Solutions by 2.9% during the third quarter. Millennium Management LLC now owns 27,698 shares of the medical equipment provider’s stock valued at $707,000 after buying an additional 783 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of BioLife Solutions by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock valued at $489,000 after buying an additional 914 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.